Quaiser Parvez and the institutional capital blueprint reshaping India's healthcare real estate corridors

India's real estate capital markets have entered a new phase of maturity, and the appointment of Quaiser Parvez as Chief Executive Officer of CapitaLand Investment India signals a decisive pivot in how institutional capital allocates across emerging verticals. With over 20 years of institutional real estate leadership experience, Parvez inherits a mandate that extends well beyond the conventional office and logistics playbook. The convergence of government-backed pharmaceutical incentives, record foreign capital inflows, and surging demand for purpose-built medical infrastructure positions healthcare and life sciences real estate as the next frontier for institutional deployment in India.

The timing is significant. India's real estate sector recorded equity capital inflows of USD 8.5 billion in the first half of 2026, the highest half-yearly figure on record, according to CBRE South Asia. Institutional real estate investment surged 90% sequentially to reach USD 2.68 billion in Q2 2026, per Vestian Research. These are structural shifts, not cyclical surges. The capital flowing into Indian real estate is increasingly searching for diversified exposure beyond Grade A office and warehousing, and healthcare real estate offers precisely the yield profile, demand resilience, and long-duration tenancy that institutional portfolios require.

Why is healthcare real estate becoming India's next institutional asset class?

Healthcare real estate globally has entered a period of accelerated institutional recognition. The global healthcare real estate market was valued at USD 1,542.5 billion in 2025 and reached USD 1,660.8 billion in 2026, according to Grand View Research, with projections pointing toward USD 2,923.9 billion by 2033 at a CAGR of 8.4%. These figures reflect a fundamental repricing of how capital markets view medical infrastructure, shifting from a niche social-impact vertical to a core allocation within diversified real estate portfolios.

India's position within this global trajectory is uniquely compelling. The country's healthcare sector delivered robust growth in FY26, with major hospital operators seeing revenue and EBITDA growth exceeding 15% year-on-year, according to EY-Parthenon's healthcare sector update. This operational performance translates directly into real estate demand. Hospital systems expanding their footprints require purpose-built facilities. Pharmaceutical companies scaling R&D operations need specialized laboratory and cleanroom infrastructure. Medical device manufacturers establishing production lines demand compliant industrial parks. Each of these requirements creates a distinct real estate vertical with long lease durations and high switching costs for tenants.

The asset class presents a compelling thesis for institutional capital precisely because of its structural demand drivers. India's demographic trajectory, with a rapidly expanding middle class demanding higher-quality healthcare, creates organic demand growth. The country's emergence as a global clinical trials hub and pharmaceutical manufacturing center adds an export-oriented demand layer. Medical tourism, which draws patients from across South Asia, the Middle East, and Africa, generates demand for integrated wellness-hospitality developments that blend clinical infrastructure with hospitality-grade patient accommodation.

For institutional investors accustomed to the risk-return profile of commercial office assets, healthcare real estate offers comparable or superior characteristics. Tenant stickiness in medical facilities far exceeds that of conventional office space, given the regulatory approvals, specialized fit-outs, and equipment investments that anchor healthcare operators to their locations.

How does the Biopharma Shakti initiative reshape the life sciences real estate pipeline?

The Union Budget 2026-27 introduced the Biopharma Shakti Initiative with an INR 10,000 crore (USD 1.1 billion) outlay to strengthen the ecosystem for biologics and biosimilars. This policy intervention directly catalyzes demand for specialized real estate, including R&D laboratories, manufacturing facilities, and integrated bio-clusters. The initiative represents one of the most targeted government interventions linking pharmaceutical policy to physical infrastructure development.

India's consolidated FDI policy further reinforces the capital architecture supporting this vertical. The policy permits 100% Foreign Direct Investment under the automatic route for the hospital sector, medical devices, and greenfield pharmaceutical projects. Brownfield pharma projects are permitted up to 74% under the automatic route. This regulatory framework eliminates the approval bottlenecks that historically constrained foreign capital from entering healthcare infrastructure at scale.

The geographic distribution of this emerging asset class is already taking shape. Hyderabad commanded approximately 35% of India's total life sciences real estate activity measured by gross leasing, establishing itself as the country's leader, followed by Bangalore at 25%, according to JLL. These cities possess the confluence of factors that life sciences tenants require: proximity to existing pharmaceutical clusters, access to a skilled scientific workforce, established logistics connectivity for cold-chain distribution, and supportive state-level industrial policies.

The Biopharma Shakti initiative accelerates a trend already visible in leasing data. Integrated bio-clusters, combining research, manufacturing, and administrative functions within campus-style developments, represent a new typology that requires institutional-grade development capabilities. These are complex projects demanding specialized design expertise, regulatory compliance infrastructure, and long development timelines. They reward patient institutional capital over opportunistic deployment.

What capital architecture does Quaiser Parvez bring to this emerging vertical?

Quaiser Parvez's career trajectory, built through leadership at institutions focused on commercial office assets and real estate investment trusts, provides precisely the capital structuring expertise that healthcare real estate demands as it transitions from a fragmented, developer-driven market to an institutionally underwritten asset class.

CapitaLand Investment, as one of Asia's largest diversified real estate investment managers, brings global operating platforms and established fund structures that can channel institutional capital into Indian healthcare real estate at scale. The company's existing presence across multiple Asian markets provides benchmarking capabilities against more mature healthcare real estate verticals in Singapore, Japan, and Australia.

The critical challenge in Indian healthcare real estate today is the gap between demand-side growth and supply-side institutional quality. Hospital operators, pharmaceutical companies, and medical device manufacturers increasingly require facilities built to international specifications, with the compliance infrastructure, environmental controls, and operational flexibility that institutional-grade development delivers. The fragmented nature of India's current healthcare real estate supply, dominated by smaller developers and owner-occupied facilities, creates a substantial opportunity for institutional platforms to introduce standardized, scalable product.

Parvez's mandate at CapitaLand Investment India arrives at an inflection point where the capital markets infrastructure for healthcare real estate is maturing rapidly. The India healthcare analytics market is expected to reach USD 16.4 billion by 2034, exhibiting a CAGR of 24.56% during 2026-2034, according to IMARC Group. This data infrastructure buildout supports the underwriting sophistication that institutional investors require before committing to healthcare-specific assets.

The convergence of record capital inflows, government policy catalysts, and executive leadership with institutional structuring experience creates conditions for healthcare real estate to emerge as a distinct allocation category within Indian institutional portfolios over the next investment cycle.

The strategic implications for India's real estate capital markets

India's real estate investment landscape has historically concentrated institutional capital across four primary verticals: office, residential, logistics and warehousing, and retail. Data centers emerged as a fifth vertical over the past three years, attracting significant institutional interest. Healthcare and life sciences real estate represents the logical next expansion of the institutional investable universe.

The asset class benefits from countercyclical demand characteristics that diversify portfolio risk. Healthcare consumption correlates weakly with business cycles, providing income stability during economic downturns. Life sciences R&D investment follows pharmaceutical pipeline dynamics rather than commercial real estate cycles. These characteristics make healthcare assets a natural complement to the more cyclically sensitive office and retail allocations that dominate most institutional Indian real estate portfolios.

GRI Institute's engagement with senior real estate leaders across India consistently surfaces healthcare infrastructure as a theme of growing strategic priority. Conversations within the GRI community reflect an institutional appetite that is moving from exploratory to actionable, with capital allocators seeking established operating partners and proven development platforms to access the vertical.

The appointment of leadership with Quaiser Parvez's profile to a platform with CapitaLand Investment's scale suggests that the institutional infrastructure for healthcare real estate in India is assembling rapidly. The question for the market is no longer whether healthcare real estate will achieve institutional asset class status in India, but which capital platforms will establish first-mover advantages in structuring the development pipelines, operating platforms, and exit mechanisms that define institutional-grade verticals.

As India's real estate sector absorbs record capital inflows and the Biopharma Shakti initiative begins channeling government resources into physical infrastructure, the leaders who architect the bridge between pharmaceutical policy and real estate capital markets will define the next decade of India's institutional investment landscape. GRI Institute will continue tracking this convergence through its research and leadership convenings across the Indian market.